AltMountain

Catalio Capital Management, LP

New York, NY · CRD 310374
Hedge fund manager

Catalio Capital Management, LP is an SEC-registered investment adviser based in New York, NY that reports managing 1 hedge fund on Form ADV. It reports $2.2 billion in regulatory assets under management. Its private funds, of all types, hold $1.4 billion in gross assets. Its disclosed U.S. stock holdings returned an estimated +18.2% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +64.1% from Q1 2025 to Q2 2026, compared with +27.4% for the S&P 500, based on 13F filings.

Regulatory assets under management
$2.2 billionForm ADV Item 5.F
Gross assets of private funds
$1.4 billionAll private fund types, Form ADV
Hedge funds managed
123 private funds in total
Employees
30Form ADV Item 5.A
Registration
SEC-registered adviserCRD 310374
Latest Form ADV
03/31/2026Disciplinary disclosures: none reported

Estimated 13F portfolio performance

Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.

Estimated from 13F · 2026 YTD+18.2%Through Q2 2026 · S&P 500 +9.5%
Estimated from 13F · 6 quarters+64.1%Q1 2025 – Q2 2026
S&P 500+27.4%Same quarters, price only
13F holdings$532.1 million39 positions, 2026-06-30
$92$128$164Q1 2025Q3 2025Q1 202613F est. $164S&P 500 $127
QuarterEst. 13F returnS&P 500
Q2 2026+22.9%+14.8%
Q1 2026-3.8%-4.6%
Q4 2025+25.6%+2.4%
Q3 2025+16.7%+7.8%
Q2 2025+2.7%+10.4%
Q1 2025-7.7%-4.5%

Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures

Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.

13F holdings as of Sep 30, 2026

All 47 share positions ($538,308,196) reported by Catalio Capital Management, LP on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.

Share of the reported 13F portfolio, ten largest positions

  • Avalyn Pharmaceuticals Inc8.99%
  • Bristol-myers Squibb Co5.79%
  • Bridgebio Pharma Inc5.20%
  • Parabilis Medicines Inc4.94%
  • Johnson & Johnson4.89%
  • Ascendis Pharma A/s4.29%
  • Arrowhead Pharmaceuticals In3.83%
  • Syndax Pharmaceuticals Inc3.57%
  • Definium Therapeutics Inc3.52%
  • Celcuity Inc3.41%
StockValue% of 13F portfolioSharesShares vs prior quarter
Avalyn Pharmaceuticals Inc$48,400,2658.99%1,698,851+1.37%
Bristol-myers Squibb Co$31,182,2785.79%499,716+21.01%
Bridgebio Pharma Inc$27,972,3045.20%425,111-6.58%
Parabilis Medicines Inc$26,608,3484.94%824,043Unchanged
Johnson & Johnson$26,340,5714.89%99,496-28.39%
Ascendis Pharma A/s$23,112,2144.29%101,445+219.42%
Arrowhead Pharmaceuticals In$20,632,9163.83%315,247New
Syndax Pharmaceuticals Inc$19,241,9883.57%1,023,510-15.81%
Definium Therapeutics Inc$18,952,5103.52%497,964-11.50%
Celcuity Inc$18,338,0283.41%230,609New
Septerna Inc$17,765,6073.30%454,015-15.32%
Guardant Health Inc$16,512,3903.07%92,579New
Protagonist Therapeutics Inc$15,838,5722.94%112,418+5.26%
10X Genomics Inc$14,821,6602.75%164,029New
Amylyx Pharmaceuticals Inc$14,721,1662.73%505,882New
Mineralys Therapeutics Inc$14,659,9372.72%583,364-10.07%
Edwards Lifesciences Corp$13,907,9652.58%161,121+29.13%
Corvus Pharmaceuticals Inc$11,767,6682.19%1,021,499-5.49%
Veradermics Inc$11,595,1652.15%95,646+108.58%
Entera Bio LTD$11,411,7632.12%3,921,568New
Disc Medicine Inc$11,305,5312.10%172,709+8.36%
Odyssey Therapeutics Inc$10,173,1831.89%457,839Unchanged
4D Molecular Therapeutics In$9,798,8151.82%684,753+45.30%
Ultragenyx Pharmaceutical In$9,044,4531.68%601,760-4.86%
Biomarin Pharmaceutical Inc$8,698,2601.62%144,971New
Annexon Inc$8,404,1891.56%1,986,806New
Rhythm Pharmaceuticals Inc$8,151,7371.51%85,614New
Structure Therapeutics Inc$8,133,6081.51%260,109-5.95%
Nektar Therapeutics$7,678,1351.43%126,817New
Immunocore Hldgs PLC$6,421,0261.19%211,985+43.19%
Cogent Biosciences Inc$5,370,2661.00%167,716New
Kailera Therapeutics Inc$5,353,1250.99%468,750Unchanged
Natera Inc$5,178,7740.96%12,530-84.75%
Fractyl Health Inc$4,813,4250.89%8,841,707+43.33%
Kardigan Inc$4,609,3750.86%312,500Unchanged
Eledon Pharmaceuticals Inc$4,141,8980.77%1,637,114-3.42%
Heartflow Inc$3,729,7080.69%74,969-87.14%
Bridgebio Oncology Therapeut$2,868,0810.53%699,532+9.85%
Korsana Biosciences Inc$2,806,4640.52%87,702New
Freenome Inc$2,491,1780.46%158,170New
Protara Therapeutics Inc$1,562,4750.29%512,287-1.51%
Karyopharm Therapeutics Inc$1,190,9530.22%976,191+3.76%
Hyperfine Inc$1,052,9490.20%1,303,155-1.28%
Metagenomi Therapeutics Inc$560,7330.10%528,993Unchanged
Faeth Therapeutics Inc$437,7130.08%14,718Unchanged
Outset Med Inc$322,3680.06%107,456-9.15%
Adarx Pharmaceuticals Inc$226,4590.04%11,357New

Changes since Jun 30, 2026

Comparing the share counts in the two quarter-end filings: 14 new positions, 6 sold out, 12 increased, 15 reduced and 6 unchanged.

Number of positions (a count, not dollars)

  • New positions14
  • Increased12
  • Unchanged6
  • Reduced15
  • Sold out6

New positions

StockValueShares
Arrowhead Pharmaceuticals In$20,632,916315,247
Celcuity Inc$18,338,028230,609
Guardant Health Inc$16,512,39092,579
10X Genomics Inc$14,821,660164,029
Amylyx Pharmaceuticals Inc$14,721,166505,882
Entera Bio LTD$11,411,7633,921,568
Biomarin Pharmaceutical Inc$8,698,260144,971
Annexon Inc$8,404,1891,986,806
Rhythm Pharmaceuticals Inc$8,151,73785,614
Nektar Therapeutics$7,678,135126,817
Cogent Biosciences Inc$5,370,266167,716
Korsana Biosciences Inc$2,806,46487,702
Freenome Inc$2,491,178158,170
Adarx Pharmaceuticals Inc$226,45911,357

Sold out

StockValue at Jun 30, 2026Shares held then
Gilead Sciences Inc$34,024,499269,309
Incyte Corp$21,722,837191,627
Axsome Therapeutics Inc.$10,569,65843,182
Dyne Therapeutics Inc$5,439,873244,929
Dianthus Therapeutics Inc$3,211,08932,941
Ataibeckley Inc$1,037,442196,858

Largest increases

StockChange in sharesChangeValue nowShares now
Ascendis Pharma A/s+69,686+219.42%$23,112,214101,445
Veradermics Inc+49,790+108.58%$11,595,16595,646
Bristol-myers Squibb Co+86,755+21.01%$31,182,278499,716
Edwards Lifesciences Corp+36,343+29.13%$13,907,965161,121
4D Molecular Therapeutics In+213,499+45.30%$9,798,815684,753
Immunocore Hldgs PLC+63,940+43.19%$6,421,026211,985
Fractyl Health Inc+2,672,958+43.33%$4,813,4258,841,707
Disc Medicine Inc+13,325+8.36%$11,305,531172,709
Protagonist Therapeutics Inc+5,619+5.26%$15,838,572112,418
Avalyn Pharmaceuticals Inc+23,021+1.37%$48,400,2651,698,851
Bridgebio Oncology Therapeut+62,718+9.85%$2,868,081699,532
Karyopharm Therapeutics Inc+35,336+3.76%$1,190,953976,191

Largest reductions

StockChange in sharesChangeValue nowShares now
Natera Inc-69,651-84.75%$5,178,77412,530
Heartflow Inc-508,086-87.14%$3,729,70874,969
Johnson & Johnson-39,450-28.39%$26,340,57199,496
Syndax Pharmaceuticals Inc-192,188-15.81%$19,241,9881,023,510
Septerna Inc-82,137-15.32%$17,765,607454,015
Definium Therapeutics Inc-64,708-11.50%$18,952,510497,964
Bridgebio Pharma Inc-29,930-6.58%$27,972,304425,111
Mineralys Therapeutics Inc-65,358-10.07%$14,659,937583,364
Corvus Pharmaceuticals Inc-59,389-5.49%$11,767,6681,021,499
Structure Therapeutics Inc-16,441-5.95%$8,133,608260,109
Ultragenyx Pharmaceutical In-30,744-4.86%$9,044,453601,760
Eledon Pharmaceuticals Inc-57,957-3.42%$4,141,8981,637,114
Outset Med Inc-10,823-9.15%$322,368107,456
Protara Therapeutics Inc-7,861-1.51%$1,562,475512,287
Hyperfine Inc-16,886-1.28%$1,052,9491,303,155

Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.

From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures

Large ownership stakes (Schedule 13D and 13G)

CompanyFilingPercent of classSharesFiledSource
Fractyl Health, Inc.13G5.6%736,807Oct 13, 2026SEC.gov ↗

A firm files Schedule 13G (passive) or 13D (it may seek to influence the company) when it beneficially owns more than 5% of a class of a public company's shares. Each row is the firm's latest such filing for that company since Oct 13, 2026, exactly as filed, and counts shares held across the firm and its affiliates, not by any single fund. An amendment can report a stake that has fallen below 5%. Holdings may have changed since the filing date. Not verified by AltMountain. Source: U.S. Securities and Exchange Commission, EDGAR.

Hedge funds filing Form D (2)

Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.

Private equity funds filing Form D (1)

Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.

Private funds reported on Form ADV (15)

Fund
Gross assets
Minimum
Owners
Adviser
Catalio Nexus Fund III, LP
Delaware, United StatesPrivate equity fund
Gross assets$365M
Minimum$500K
Owners327
AdviserCatalio Capital Management, LP
Catalio Nexus Fund IV, LP
Delaware, United StatesPrivate equity fund
Gross assets$191M
Minimum$1.0M
Owners166
AdviserCatalio Capital Management, LP
Catalio Public Equities Master Fund, LP
Delaware, United StatesHedge fund
Gross assets$109M
Minimum$1.0M
Owners59
AdviserCatalio Capital Management, LP
Catalio Nexus Fund II, LP
Delaware, United StatesPrivate equity fund
Gross assets$87.9M
Minimum$500K
Owners151
AdviserCatalio Capital Management, LP
Catalio Structured Opportunities Fund I LP
Delaware, United StatesPrivate fund
Gross assets$54.5M
Minimum$1.0M
Owners83
AdviserCatalio Capital Management, LP
Catalio Genesis Fund I, LLC
Delaware, United StatesVenture capital fund
Gross assets$46.8M
Minimum$500K
Owners54
AdviserCatalio Capital Management, LP
Catalio Genesis Fund II, LLC
Delaware, United StatesVenture capital fund
Gross assets$43.4M
Minimum$250K
Owners100
AdviserCatalio Capital Management, LP
Catalio Genesis Fund III, LLC
Delaware, United StatesVenture capital fund
Gross assets$35.8M
Minimum$250K
Owners77
AdviserCatalio Capital Management, LP
Catalio Structured Opportunities Aiv I LP
Delaware, United StatesPrivate fund
Gross assets$30.7M
Minimum$1.0M
Owners80
AdviserCatalio Capital Management, LP
Catalio Access Fund V, LLC
Delaware, United StatesVenture capital fund
Gross assets$15.5M
Minimum$250K
Owners60
AdviserCatalio Capital Management, LP
Catalio Genesis Fund IV, LLC
Delaware, United StatesVenture capital fund
Gross assets$11.3M
Minimum$250K
Owners51
AdviserCatalio Capital Management, LP
Catalio Nexus Fund I, LP
Delaware, United StatesVenture capital fund
Gross assets$9.3M
Minimum$250K
Owners58
AdviserCatalio Capital Management, LP
Catalio Access Fund VI, LLC
Delaware, United StatesVenture capital fund
Gross assets$8.3M
Minimum$250K
Owners36
AdviserCatalio Capital Management, LP
Catalio Access Fund I, LLC
Delaware, United StatesVenture capital fund
Gross assets$5.3M
Minimum$250K
Owners44
AdviserCatalio Capital Management, LP
Catalio Special Opportunities Fund I, LLC
Delaware, United StatesVenture capital fund
Gross assets$737K
Minimum$350K
Owners5
AdviserCatalio Capital Management, LP

As reported in the adviser's Form ADV filed Mar 26, 2024. Funds also listed from Form D are shown above.

From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures⁠​​‌‌‌‌‌‌‌​‌‌‌‌‌‌‌‌​‌⁠